Piper Sandler analyst Yasmeen Rahimi initiated coverage of Unicycive Therapeutics with an Overweight rating and $9 price target. The analyst says Unicycive trading at cash and significantly below its value. The company has a “major upside ahead” as its lead asset, OLC, is a wholly-owned phosphate binding agent currently in late-stage development for hyperphosphatemia, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UNCY:
- Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
- Unicycive Therapeutics reports FY23 EPS ($1.28), consensus ($1.24)
- Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
- Unicycive Therapeutics to sell 50,000 shares at $1,000 in private placement
- Unicycive Announces $50 Million Private Placement
